Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long LLY ETF

25.15
+0.32001.29%
Post-market: 25.05-0.1000-0.40%19:54 EDT
Volume:138.26K
Turnover:3.43M
Market Cap:87.14M
PE:- -
High:25.20
Open:24.48
Low:24.11
Close:24.83
52wk High:31.19
52wk Low:14.51
Shares:3.47M
Float Shares:3.47M
Volume Ratio:0.39
T/O Rate:3.99%
Dividend:0.71
Dividend Rate:2.80%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 22

Viking Therapeutics Stock Surges 36%. it Could Challenge Lilly and Novo's Obesity Empire.

Dow Jones
·
Sep 22

Eli Lilly and Company Breaks Ground on $6.5 Billion Houston Manufacturing Site

MT Newswires Live
·
Sep 22

Eli Lilly: Breaks Ground on Fifth U.S. API Manufacturing Site in Houston

THOMSON REUTERS
·
Sep 22

Eli Lilly: Houston Facility to Manufacture Active Pharmaceutical Ingredients for Medicines Like Foundayo

THOMSON REUTERS
·
Sep 22

Sector Update: Healthcare

MT Newswires Live
·
Sep 22

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients taking Foundayo

TIPRANKS
·
Sep 22

Top Midday Stories: Paramount Skydance Settles With US States to Pave Way for Warner Bros. Deal; Anthropic Now Eyeing November IPO

MT Newswires Live
·
Sep 21

Novo Nordisk Says New Obesity Drug Outperformed Lilly's Zepbound in Phase 3 Trial

Dow Jones
·
Sep 21

Novo Stock (NVO) Sinks Despite Beating Eli Lilly in New CagriSema Obesity Trial

TIPRANKS
·
Sep 21

Oura Files for Initial Public Offering on Nasdaq

MT Newswires Live
·
Sep 21

Smart Ring Maker Oura Eyes $15.6 Billion IPO Valuation in Fall Listings Demand Test

Reuters
·
Sep 21

Oura - Eli Lilly Interested in Purchasing up to $100 Mln; Dragoneer up to $300 Mln in IPO - SEC Filing

THOMSON REUTERS
·
Sep 21

Novo Says Its Next-Gen Obesity Drug Tops Lilly Rival in Late-Stage Study

Reuters
·
Sep 21

Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports

TIPRANKS
·
Sep 20

Retension Pharmaceuticals, TRex Bio File for US IPO as Biotech Momentum Continues

Reuters
·
Sep 19

Sector Update: Healthcare

MT Newswires Live
·
Sep 19

Eli Lilly reports full FDA approval of Inluriyo combo for certain breast cancers

TIPRANKS
·
Sep 19

US FDA Approves Lilly Inluriyo-Verzenio Combo for ESR1-Mutated Metastatic Breast Cancer

Reuters
·
Sep 19

U.S. FDA Approves Inluriyo (Imlunestrant) in Combination with Verzenio (Abemaciclib) for Adults with Er+, Her2-, Esr1-Mutated Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Sep 19